We narrowed to 569 results for: uros

#100838-AAV1

Ready-to-use AAV1 particles produced from pAAV.Syn.Flex.GCaMP6m.WPRE.SV40 (#100838). In addition to the viral particles, you will also receive purified pAAV.Syn.Flex.GCaMP6m.WPRE.SV40 plasmid DNA. Syn-driven, Cre-dependent GCaMP6M calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

May 17, 2018

Academic Institutions and Nonprofits only

#26968-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

Feb. 20, 2018

Academic Institutions and Nonprofits only

#99118-AAV2

Ready-to-use AAV2 particles produced from pAAV-CAG-tTA (#99118). In addition to the viral particles, you will also receive purified pAAV-CAG-tTA plasmid DNA. CAG-driven expression of tetracycline-controlled transactivator (tTA). These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

June 26, 2024

Academic Institutions and Nonprofits only

#100835-AAV2

Ready-to-use AAV2 particles produced from pAAV.CAG.Flex.GCaMP6f.WPRE.SV40 (#100835). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.GCaMP6f.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent GCaMP6f calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

July 8, 2020

Academic Institutions and Nonprofits only

#100839-AAV1

Ready-to-use AAV1 particles produced from pAAV.CAG.Flex.GCaMP6m.WPRE.SV40 (#100839). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.GCaMP6m.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent GCaMP6m calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

May 11, 2018

Academic Institutions and Nonprofits only

#100839-AAV9

Ready-to-use AAV9 particles produced from pAAV.CAG.Flex.GCaMP6m.WPRE.SV40 (#100839). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.GCaMP6m.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent GCaMP6m calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

May 14, 2018

Academic Institutions and Nonprofits only

#98929-AAV5

Ready-to-use AAV5 particles produced from pAAV.hSyn.iGluSnFr.WPRE.SV40 (#98929). In addition to the viral particles, you will also receive purified pAAV.hSyn.iGluSnFr.WPRE.SV40 plasmid DNA. Synapsin-driven, iGluSnFr glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2013 Feb;10(2):162-70. doi:

Feb. 27, 2018

Academic Institutions and Nonprofits only

#58892-AAV5

Ready-to-use AAV5 particles produced from pAAV-GFAP104-ChR2-mCherry (#58892). In addition to the viral particles, you will also receive purified pAAV-GFAP104-ChR2-mCherry plasmid DNA. GFAP -driven, expression of humanized ChR2 H134R mutant fused to mCherry, for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Perea et al Nat Commun. 2014;5:3262. doi: 10.1038/nc

Jan. 14, 2026

Academic Institutions and Nonprofits only

#92207-AAV1

Ready-to-use AAV1 particles produced from TRE-ChrimsonR-mCherry (#92207). In addition to the viral particles, you will also receive purified TRE-ChrimsonR-mCherry plasmid DNA. TRE-driven ChrimsonR-mCherry expression for optogenetic neural activation. These AAV preparations are suitable purity for injection into animals.

Alice Ting

Wang et al Nat Biotechnol. 2017 Jun 26. doi: 10.103

Nov. 13, 2025

Academic Institutions and Nonprofits only

#98930-AAV1

Ready-to-use AAV1 particles produced from pENN.AAV.GFAP.iGluSnFr.WPRE.SV40 (#98930). In addition to the viral particles, you will also receive purified pENN.AAV.GFAP.iGluSnFr.WPRE.SV40 plasmid DNA. GFAP-driven glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2013 Feb;10(2):162-70. doi:

March 15, 2018

Academic Institutions and Nonprofits only

#98931-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSyn.Flex.iGluSnFr.WPRE.SV40 (#98931). In addition to the viral particles, you will also receive purified pAAV.hSyn.Flex.iGluSnFr.WPRE.SV40 plasmid DNA. Synapsin-driven, Cre-dependent, iGluSnFr glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2013 Feb;10(2):162-70. doi:

April 3, 2018

Academic Institutions and Nonprofits only

#98931-AAV5

Ready-to-use AAV5 particles produced from pAAV.hSyn.Flex.iGluSnFr.WPRE.SV40 (#98931). In addition to the viral particles, you will also receive purified pAAV.hSyn.Flex.iGluSnFr.WPRE.SV40 plasmid DNA. Synapsin-driven, Cre-dependent, iGluSnFr glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2013 Feb;10(2):162-70. doi:

Feb. 28, 2018

Academic Institutions and Nonprofits only

#98932-AAV5

Ready-to-use AAV5 particles produced from pAAV.CAG.Flex.iGluSnFr.WPRE.SV40 (#98932). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.iGluSnFr.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2013 Feb;10(2):162-70. doi:

Feb. 28, 2018

Academic Institutions and Nonprofits only

#98932-AAV1

Ready-to-use AAV1 particles produced from pAAV.CAG.Flex.iGluSnFr.WPRE.SV40 (#98932). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.iGluSnFr.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2013 Feb;10(2):162-70. doi:

Feb. 28, 2018

Academic Institutions and Nonprofits only

#98932-AAV9

Ready-to-use AAV9 particles produced from pAAV.CAG.Flex.iGluSnFr.WPRE.SV40 (#98932). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.iGluSnFr.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2013 Feb;10(2):162-70. doi:

Feb. 28, 2018

Academic Institutions and Nonprofits only

#26969-AAV5

Ready-to-use AAV5 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

March 7, 2018

Academic Institutions and Nonprofits only

#26969-AAV9

Ready-to-use AAV9 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

March 7, 2018

Academic Institutions and Nonprofits only

#26969-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

May 9, 2018

Academic Institutions and Nonprofits only

#111262-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSynapsin1-axon-GCaMP6s (#111262). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6s plasmid DNA. Synapsin-driven, axon-targeted GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

May 8, 2019

Academic Institutions and Nonprofits only

#112000-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSynapsin1-axon-GCaMP6f (#112000). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6f plasmid DNA. Synapsin-driven, axon-targeted GCaMP6f calcium sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

March 12, 2021

Academic Institutions and Nonprofits only

#99133-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-fDIO-mNeonGreen (#99133). In addition to the viral particles, you will also receive purified pAAV-CAG-fDIO-mNeonGreen plasmid DNA. CAG-driven, Flp-dependent mNeonGreen expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

Jan. 6, 2022

Academic Institutions and Nonprofits only

#60658-AAV8

Ready-to-use AAV8 particles produced from pAAV-EF1α-F-FLEX-mNaChBac-T2A-tdTomato (#60658). In addition to the viral particles, you will also receive purified pAAV-EF1α-F-FLEX-mNaChBac-T2A-tdTomato plasmid DNA. CAG-driven, Flp-dependent expression of the voltage-gated Na+ channel mNaChBac-T2A-tdTomato. These AAV preparations are suitable purity for injection into animals.

Massimo Scanziani

Xue et al Nature. 2014 Jul 31;511(7511):596-600. d

Oct. 21, 2024

Academic Institutions and Nonprofits only

#99130-AAV1

Ready-to-use AAV1 particles produced from pAAV-mDlx-NLS-mRuby2 (#99130). In addition to the viral particles, you will also receive purified pAAV-mDlx-NLS-mRuby2 plasmid DNA. mDlx-driven NLS-mRuby2 expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

Jan. 14, 2019

Academic Institutions and Nonprofits only

#99120-AAV1

Ready-to-use AAV1 particles produced from pAAV-ihSyn1-tTA (#99120). In addition to the viral particles, you will also receive purified pAAV-ihSyn1-tTA plasmid DNA. Expression of the tet-off transactivator from an inducible synapsin promoter. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

April 4, 2019

Academic Institutions and Nonprofits only

#99130-AAV9

Ready-to-use AAV9 particles produced from pAAV-mDlx-NLS-mRuby2 (#99130). In addition to the viral particles, you will also receive purified pAAV-mDlx-NLS-mRuby2 plasmid DNA. mDlx-driven NLS-mRuby2 expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

Sept. 8, 2020

Academic Institutions and Nonprofits only

#175274-AAV1

Ready-to-use AAV1 particles produced from pAAV-rtTA (#175274). In addition to the viral particles, you will also receive purified pAAV-rtTA plasmid DNA. Syn-driven expression of reverse tetracycline-controlled transactivator. These AAV preparations are suitable purity for injection into animals.

Wei Xu

Li et al Nat Methods. 2021 Nov 25. pii: 10.1038/s

Jan. 15, 2026

Academic Institutions and Nonprofits only

#26969-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

Feb. 14, 2018

Academic Institutions and Nonprofits only

#112007-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-GCaMP6s-P2A-mRuby3 (#112007). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-GCaMP6s-P2A-mRuby3 plasmid DNA. hSyn-driven expression of calcium sensor GCaMP6s and bicistronic mRuby3. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

Feb. 14, 2022

Academic Institutions and Nonprofits only

#140275-AAV1

Ready-to-use AAV1 particles produced from pAAV-N-RAM-d2tTA-TRE-mKate2 (#140275). In addition to the viral particles, you will also receive purified pAAV-N-RAM-d2tTA-TRE-mKate2 plasmid DNA. RAM-containing and TRE-driven expression of mKate2. These AAV preparations are suitable purity for injection into animals.

Yingxi Lin

Sun et al Cell. 2020 Apr 16;181(2):410-423.e17. do

Jan. 15, 2026

Academic Institutions and Nonprofits only

#99121-AAV1

Ready-to-use AAV1 particles produced from pAAV-ihSyn1-DIO-tTA (#99121). In addition to the viral particles, you will also receive purified pAAV-ihSyn1-DIO-tTA plasmid DNA. Cre-dependent expression of the tet-off transactivator from an inducible synapsin promoter. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

April 4, 2019

Academic Institutions and Nonprofits only

#111261-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-axon-GCaMP6m (#111261). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6m plasmid DNA. Synapsin-driven expression of calcium sensor GCaMP6m in axons. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

Sept. 27, 2023

Academic Institutions and Nonprofits only

#99130-AAV5

Ready-to-use AAV5 particles produced from pAAV-mDlx-NLS-mRuby2 (#99130). In addition to the viral particles, you will also receive purified pAAV-mDlx-NLS-mRuby2 plasmid DNA. mDlx-driven NLS-mRuby2 expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

Oct. 29, 2025

Academic Institutions and Nonprofits only

#210400-AAV2

Ready-to-use AAV2 particles produced from PRS_8-GCaMP8m (#210400). In addition to the viral particles, you will also receive purified PRS_8-GCaMP8m plasmid DNA. PRS-driven expression of calcium sensor GCaMP8m. These AAV preparations are suitable purity for injection into animals.

Simon Wiegert

Wissing et al PLoS Biol. 2025 Jul 7;23(7):e3003228. do

Feb. 6, 2026

Academic Institutions and Nonprofits only

#18916-AAV1

Ready-to-use AAV1 particles produced from AAV-FLEX-rev-ChR2(H134R)-mCherry (#18916). In addition to the viral particles, you will also receive purified AAV-FLEX-rev-ChR2(H134R)-mCherry plasmid DNA. CAG-driven, cre-dependent, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Scott Sternson

Atasoy et al J Neurosci. 2008 Jul 9. 28(28):7025-30.

Feb. 21, 2018

Academic Institutions and Nonprofits only

#112006-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-GCaMP6s-P2A-mKate2 (#112006). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-GCaMP6s-P2A-mKate2 plasmid DNA. hSyn-driven expression of calcium sensor GCaMP6s and bicistronic mKate2. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

Feb. 14, 2022

Academic Institutions and Nonprofits only

#99130-AAV2

Ready-to-use AAV2 particles produced from pAAV-mDlx-NLS-mRuby2 (#99130). In addition to the viral particles, you will also receive purified pAAV-mDlx-NLS-mRuby2 plasmid DNA. mDlx-driven NLS-mRuby2 expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

Sept. 27, 2023

Academic Institutions and Nonprofits only

#99130-AAV8

Ready-to-use AAV8 particles produced from pAAV-mDlx-NLS-mRuby2 (#99130). In addition to the viral particles, you will also receive purified pAAV-mDlx-NLS-mRuby2 plasmid DNA. mDlx-driven NLS-mRuby2 expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

May 12, 2023

Academic Institutions and Nonprofits only

#125560-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-dLight1.3b (#125560). In addition to the viral particles, you will also receive purified pAAV-CAG-dLight1.3b plasmid DNA. CAG-driven expression of dLight1.3b dopamine sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

Oct. 18, 2021

Academic Institutions and Nonprofits only

#135762-AAV9

Ready-to-use AAV9 particles produced from pAAV-syn-dLight1.3b (#135762). In addition to the viral particles, you will also receive purified pAAV-syn-dLight1.3b plasmid DNA. Syn-driven expression of dLight1.3b dopamine sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

Oct. 18, 2021

Academic Institutions and Nonprofits only

#125560-AAV5

Ready-to-use AAV5 particles produced from pAAV-CAG-dLight1.3b (#125560). In addition to the viral particles, you will also receive purified pAAV-CAG-dLight1.3b plasmid DNA. CAG-driven expression of dLight1.3b dopamine sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

Oct. 15, 2020

Academic Institutions and Nonprofits only